Aurinia Pharmaceuticals, Inc. (AUPH)
16.10
-0.01
(-0.06%)
USD |
NASDAQ |
Sep 11, 16:00
16.10
0.00 (0.00%)
After-Hours: 06:47
Aurinia Pharmaceuticals Enterprise Value : 1.761B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 1.761B |
| September 10, 2026 | 1.762B |
| September 09, 2026 | 1.781B |
| September 08, 2026 | 1.757B |
| September 04, 2026 | 1.758B |
| September 03, 2026 | 1.763B |
| September 02, 2026 | 1.786B |
| September 01, 2026 | 1.754B |
| August 31, 2026 | 1.762B |
| August 28, 2026 | 1.786B |
| August 27, 2026 | 1.811B |
| August 26, 2026 | 1.819B |
| August 25, 2026 | 1.847B |
| August 24, 2026 | 1.823B |
| August 21, 2026 | 1.834B |
| August 20, 2026 | 1.916B |
| August 19, 2026 | 1.770B |
| August 18, 2026 | 1.654B |
| August 17, 2026 | 1.653B |
| August 14, 2026 | 1.677B |
| August 13, 2026 | 1.639B |
| August 12, 2026 | 1.674B |
| August 11, 2026 | 1.664B |
| August 10, 2026 | 1.674B |
| August 07, 2026 | 1.728B |
| Date | Value |
|---|---|
| August 06, 2026 | 1.765B |
| August 05, 2026 | 1.640B |
| August 04, 2026 | 1.605B |
| August 03, 2026 | 1.557B |
| July 31, 2026 | 1.599B |
| July 30, 2026 | 1.615B |
| July 29, 2026 | 1.639B |
| July 28, 2026 | 1.609B |
| July 27, 2026 | 1.644B |
| July 24, 2026 | 1.661B |
| July 23, 2026 | 1.647B |
| July 22, 2026 | 1.658B |
| July 21, 2026 | 1.700B |
| July 20, 2026 | 1.648B |
| July 17, 2026 | 1.742B |
| July 16, 2026 | 1.740B |
| July 15, 2026 | 1.761B |
| July 14, 2026 | 1.745B |
| July 13, 2026 | 1.752B |
| July 10, 2026 | 1.718B |
| July 09, 2026 | 1.826B |
| July 08, 2026 | 1.778B |
| July 07, 2026 | 1.777B |
| July 06, 2026 | 1.680B |
| July 02, 2026 | 1.696B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| enGene Therapeutics, Inc. | -112.50M |
| Medicus Pharma Ltd. | 14.37M |
| Xenon Pharmaceuticals, Inc. | 4.750B |
| Psyence Biomedical Ltd. | -- |
| Altimmune, Inc. | 345.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.41M |
| Revenue (Quarterly) | 83.22M |
| Total Expenses (Quarterly) | 45.81M |
| EPS Diluted (Quarterly) | 0.2802 |
| Gross Profit Margin (Quarterly) | 92.12% |
| Profit Margin (Quarterly) | 44.96% |
| Earnings Yield | 14.21% |
| Operating Earnings Yield | 6.41% |
| Normalized Earnings Yield | 14.21 |